Board of Directors

Leif Darner owns all shares in Darner Asset Management AB. He is also a board member of I-Tech AB and of Flowserve Corporation. Prior to that he was a member of the Board of Management at AkzoNobel Bv, responsible for Coatings from 2008 and for Chemicals from 2004. Prior to this he has held several executive positions including CEO of BU Marine & Protective Coatings at Courtaulds plc and CEO of International Färg AB.

Shareholdings: 173,333

Share awards: 125,000

Education: M.Sc. in Business Administration from the University of Gothenburg, School of Business, Economics and Law.

Other assignments: Board member of Darner Asset Management AB, I-Tech AB and Flowserve Corporation.

Independent of the company and its senior management and independent of major shareholders of the company.

Maarten Kraan has extensive experience in biomedicine and has, among others, held a senior position at AstraZeneca AB where he was responsible for the research and development of medicines for respiratory, inflammatory and autoimmune symptoms.

Shareholdings: –

Share awards: 125,000

Education: Doctor’s degree in rheumatology at the University of Leiden.

Other assignments: Maarten Kraan is a board member of Toleranzia AB and CDS Gmbh.

Independent of the company and its senior management and independent of major shareholders of the company.

Jacob Gunterberg is a partner at HealthCap since 2007 and has extensive experience in venture capital investment operations and corporate finance in life science. Jacob Gunterberg is, among others, a board member of Trimb Holding AB, HealthCap Orx Holdings GP AB, Carisma Therapeutics Inc. and former chairman of INIM Pharma AB.

Shareholdings: –

Share awards: –

Education: M.Sc. in Business Administration and Economics from Lund University.

Other assignments: Board member Skipjack AB, Ancilla AB, EllAug AB and Tova Skrenen Stockholm AB. Chairman and board member of JUSG Aktiebolag.

Independent of the company and its senior management but dependent of major shareholders of the company.

Mr. Schikan is former CEO of Prosensa (aquired by BioMarin). His previous assignments include leadership roles at Genzyme (acquired by Sanofi) and Organon (acquired by Schering Plough). He previously served on the boards of Hansa Biopharma, Asceneuron, Wilson Therapeutics (acquired by Alexion) and Therachon (aquired by Pfizer).

Shareholdings: –

Share awards: 125,000

Education: Doctor of Pharmacy (PharmD) from the University of Utrecht.

Other assignments:Chairman of Interna, The Netherlands and Complix, Belgium. Board member of Swedish Orphan Biovitrum, Sweden, VectivBio, Switzerland, Pharvaris, The Netherlands and the Dutch Top Sector Life Sciences & Health. Advisor to various organisations in Life Sciences & Health.

Independent of the company and its senior management and independent of major shareholders of the company.